The distribution of human rectal aberrant crypt foci and criteria for defining the counting area

Fujii,Tetsuro; Sakai,Eiji; Takahashi,Hirokazu; Yamada,Eiji; Ohkubo,Hidenori; Higurashi,Takuma; Nakajima,Atsushi

doi:10.3892/ol.2017.6003

The distribution of human rectal aberrant crypt foci and criteria for defining the counting area

Authors:
- Tetsuro Fujii
- Eiji Sakai
- Hirokazu Takahashi
- Eiji Yamada
- Hidenori Ohkubo
- Takuma Higurashi
- Atsushi Nakajima
View Affiliations

Affiliations: Department of Gastroenterology and Hepatology, Yokohama City University School of Medicine, Yokohama, Kanagawa 236-0004, Japan
Published online on: April 7, 2017 https://doi.org/10.3892/ol.2017.6003
Pages: 4501-4504

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Aberrant crypt foci (ACF) are considered as a useful surrogate biomarker for colorectal cancer, although their biological significance still remains controversial. We conducted this study to clarify whether differences in the ACF counting area might have led to the discrepancies in the ACF counts among previous reports. A endoscopist proficient in ACF counting performed high‑magnification chromoscopic colonoscopy in 45 subjects and investigated the distribution of ACF in four bowel segments (middle Houston valve to the dentate line and distal rectum 0‑5, 5‑10 and 10‑15 cm). We also investigated whether the patient physique might affect the distance from the middle Houston valve to the dentate line. The prevalence of ACF was 84% and most of the ACF (170/210, 81%) were located in the bowel segment from the middle Houston valve to the dentate line. The number of ACF was significantly correlated with the bowel segment in which the counting was performed: Dentate line to the middle Houston valve and distal rectum within 0‑15 cm (r=0.94, P<0.001). The patient physique did not affect the distance from the middle Houston valve to the dentate line. In conclusion, the definition of the ACF counting area may not affect the results of ACF counting.

View Figures

View References

1	Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS, Waye JD, Schapiro M, Bond J, Panish JF, et al: Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med. 329:1977–1981. 1993. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
3	Bird RP: Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: Preliminary findings. Cancer Lett. 37:147–151. 1987. View Article : Google Scholar : PubMed/NCBI
4	McLellan EA and Bird RP: Aberrant crypts: Potential preneoplastic lesions in the murine colon. Cancer Res. 48:6187–6192. 1988.PubMed/NCBI
5	McLellan EA, Medline A and Bird RP: Dose response and proliferative characteristics of aberrant crypt foci: Putative preneoplastic lesions in rat colon. Carcinogenesis. 12:2093–2098. 1991. View Article : Google Scholar : PubMed/NCBI
6	McLellan EA, Medline A and Bird RP: Sequential analyses of the growth and morphological characteristics of aberrant crypt foci: Putative preneoplastic lesions. Cancer Res. 51:5270–5274. 1991.PubMed/NCBI
7	Pretlow TP, Barrow BJ, Ashton WS, O'Riordan MA, Pretlow TG, Jurcisek JA and Stellato TA: Aberrant crypts: Putative preneoplastic foci in human colonic mucosa. Cancer Res. 51:1564–1567. 1991.PubMed/NCBI
8	Takayama T, Katsuki S, Takahashi Y, Ohi M, Nojiri S, Sakamaki S, Kato J, Kogawa K, Miyake H and Niitsu Y: Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med. 339:1277–1284. 1998. View Article : Google Scholar : PubMed/NCBI
9	Adler DG, Gostout CJ, Sorbi D, Burgart LJ, Wang L and Harmsen WA: Endoscopic identification and quantification of aberrant crypt foci in the human colon. Gastrointest Endosc. 56:657–662. 2002. View Article : Google Scholar : PubMed/NCBI
10	Hurlstone DP, Karajeh M, Sanders DS, Drew SK and Cross SS: Rectal aberrant crypt foci identified using high-magnification-chromoscopic colonoscopy: Biomarkers for flat and depressed neoplasia. Am J Gastroentrol. 100:1283–1289. 2005. View Article : Google Scholar
11	Seike K, Koda K, Oda K, Kosugi C, Shimizu K, Nishimura M, Shioiri M, Takano S, Ishikura H and Miyazaki M: Assessment of rectal aberrant crypt foci by standard chromoscopy and its predictive value for colonic advanced neoplasms. Am J Gastroenterol. 101:1362–1369. 2006. View Article : Google Scholar : PubMed/NCBI
12	Kim J, Ng J, Arozulllah A, Ewing R, Llor X, Carroll RE and Benya RV: Aberrant crypt focus size predicts distal polyp histopathology. Cancer Epidemiol Biomarkers Prev. 17:1155–1162. 2008. View Article : Google Scholar : PubMed/NCBI
13	Rudolph RE, Dominitz JA, Lampe JW, Levy L, Qu P, Li SS, Lampe PD, Bronner MP and Potter JD: Risk factors for colorectal cancer in relation to number and size of aberrant crypt foci in humans. Cancer Epidemiol Biomarkers Prev. 14:605–608. 2005. View Article : Google Scholar : PubMed/NCBI
14	Moxon D, Raza M, Kenney R, Ewing R, Arozullah A, Mason JB and Carroll RE: Relationship of aging and tobacco use with the development of aberrant crypt foci in a predominantly African-American population. Clin Gastroenterol Hepatol. 3:271–278. 2005. View Article : Google Scholar : PubMed/NCBI
15	Stevens RG, Swede H, Heinen CD, Jablonski M, Grupka M, Ross B, Parente M, Tirnauer JS, Giardina C, Rajan TV, et al: Aberrant crypt foci in patients with a positive family history of sporadic colorectal cancer. Cancer Lett. 248:262–268. 2007. View Article : Google Scholar : PubMed/NCBI
16	Sakai E, Takahashi H, Kato S, Uchiyama T, Hosono K, Endo H, Maeda S, Yoneda M, Taguri M and Nakajima A: Investigation of the prevalence and number of aberrant crypt foci associated with human colorectal neoplasm. Cancer Epidemiol Biomaekers Prev Res. 20:1918–1924. 2011. View Article : Google Scholar
17	Mutch MG, Schoen RE, Fleshman JW, Rall CJ, Dry S, Seligson D, Charabaty A, Chia D, Umar A, Viner J, et al: A multicenter study of prevalence and risk factors for aberrant crypt foci. Clin Gastroenterol Hepatol. 7:568–574. 2009. View Article : Google Scholar : PubMed/NCBI
18	Cho NL, Redston M, Zauber AG, Carothers AM, Hornick J, Wilton A, Sontag S, Nishioka N, Giardiello FM, Saltzman JR, et al: Aberrant crypt foci in the adenoma prevention with celecoxib trial. Cancer Prev Res. 1:21–31. 2008. View Article : Google Scholar
19	Hosono K, Endo H, Takahashi H, Sugiyama M, Sakai E, Uchiyama T, Suzuki K, Iida H, Sakamoto Y, Yoneda K, et al: Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res. 3:1077–1083. 2010. View Article : Google Scholar
20	Takayama T, Nagashima H, Maeda M, Nojiri S, Hirayama M, Nakano Y, Takahashi Y, Sato Y, Sekikawa H, Mori M, et al: Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps. Clin Cancer Res. 17:3803–3811. 2011. View Article : Google Scholar : PubMed/NCBI
21	Ezuka A, Sakai E, Kawana K, Nagase H, Kakuta Y, Uchiyama S, Ohkubo H, Higurashi T, Nonaka T, Endo H, et al: Association between factors associated with colorectal cancer and rectal aberrant crypt foci in humans. Oncol Lett. 10:3689–3695. 2015.PubMed/NCBI
22	Ohkubo H, Takahashi H, Yamada E, Sakai E, Higurashi T, Uchiyama T, Hosono K, Endo H, Taguri M and Nakajima A: Natural history of human aberrant crypt foci and correlation with risk factors for colorectal cancer. Oncol Rep. 27:1475–1480. 2012.PubMed/NCBI